[#JJC2023 - Les Lauréats] Un GRAND BRAVO aux lauréats. Prix Jeunes Talents Oral : Claudia Pasqualini - Gustave Roussy Candice Merle - Institut Curie Isabella Hofer - Institut Curie Prix Jeunes Talents Poster : Jeremy Baude - Centre Georges Francois Leclerc - Dijon

Prix Kerner : Armelle Guingand - Institut de Biologie Moléculaire et Cellulaire – Strasbourg CNRS_IBMP Anaïs Perrichet - Centre de Recherche Lipides, Nutrition, Cancer - Dijon Nicolas Roussot, MD, PhD student - CGFL - Centre Georges-François Leclerc @univbourgogne

New #JITC short report: FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report bit.ly/3QcopkZ Nicolas Roussot, MD, PhD student GHIRINGHELLI Francois

Proud to share our work in #JITC : - A genomic data set of 545 ICB-treated patients - Patients with no FGF/FGFR amplification had longer PFS and OS - FGF/FGFR amplification were not associated with prognosis ➡️ We identified a predictive biomarker of ICI resistance Journal for ImmunoTherapy of Cancer

FDA approves pembrolizumab with chemotherapy for biliary tract cancer fda.gov/drugs/resource… 👉good news, more options for our patients... 🧐Let's see how long it will take to get it approved by EMA... ESMO - Eur. Oncology EASLnews ILCA #livertwitter

Let’s take a closer look at the recent #JITC article, “FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report”, by Nicolas Roussot, MD, PhD student GHIRINGHELLI Francois at CGFL 1/9

➡️ A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer. ➡️ Phase I multi-organes évaluant une association d'aPDL1, aTIGIT et radiothérapie stéréotaxique doi.org/10.1186/s12885…

New research: FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy: Background Advanced biliary tract cancer (BTC) has a poor prognosis. Gemcitabine with platinum chemotherapy… frontiersin.org/articles/10.33… #oncology

FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy. ➡️ Survie globale médiane : 9.0 mois ➡️ Survie sans progression médiane : 5.2 mois ➡️ Taux de réponse objective : 23.1% doi.org/10.3389/fonc.2… Frontiers - Oncology

Very pleased to present the results of the TASKIN study here at #ESMOGI in Munich 🇩🇪 Phase I study evaluating the association of FTD/TPI + bevacizumab + XB2001 (IL1a mAb) in mCRC patients after failure of 5FU, oxaliplatin, irinotecan. ESMO - Eur. Oncology CGFL

New Research: Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, KEAP1/STK11 co-mutated metastatic NSCLC frontiersin.org/articles/10.33… #FrontiersIn #Immunology

📄 Très heureux de partager notre travail dans ce case report publié dans Frontiers - Immunology : la caractérisation immunitaire d'une pseudoprogression chez un patient atteint d'un NSCLC métastatique, PD-L1 négatif, TMB-low, co-muté KEAP1/STK11 CGFL

Happy to share results of our new clinical trial:nature.com/articles/s4139… Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial Let me explain you the story 1/9